Nimbus Named by FierceBiotech as One of the “Fierce 15” of 2013

  Nimbus Named by FierceBiotech as One of the “Fierce 15” of 2013

Business Wire

CAMBRIDGE, Mass. -- September 24, 2013

Nimbus Discovery, LLC, a biotechnology company discovering novel medicines
against exciting but previously inaccessible disease targets, today announced
that the company has been named by FierceBiotech as one of 2013's Fierce 15,
designating it as one of the most promising private biotechnology companies in
the industry. Every year FierceBiotech evaluates hundreds of private companies
from around the world for its annual Fierce 15 list, which is based on a
variety of factors such as the strength of its technology, partnerships,
venture backers and a competitive market position. The Fierce 15 celebrates
the spirit of being "fierce" – championing innovation and creativity, even in
the face of intense competition. A complete list of "Fierce 15" companies –
the online newsletter's eleventh annual selection – is available online at

“Within two years of its Series A financing, Nimbus Discovery has grown from a
great idea with an interesting list of investors to an exciting company on the
verge of clinical trials with drugs against some of the most exciting targets
in oncology and other fields,” says FierceBiotech Executive Editor Ryan

“Nimbus is honored to be chosen by the editors of FierceBiotech as one of this
year’s Fierce 15 – a welcomed acknowledgement of our company’s innovative and
creative drug discovery approach,” said Jonathan Montagu, Vice President,
Business Development and Operations of Nimbus.

“Nimbus is successfully solving hard chemistry problems for the most
sought-after disease targets in an effort to deliver breakthrough medicines,”
said Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer of Nimbus. “We
believe that achieving this goal requires a fundamentally deeper understanding
of drug pharmacology. Our progress to date has been enabled through
cutting-edge technology and the insights of our industry-leading team,
Scientific Advisory Board, Board of Directors and drug-discovery

Using its computationally-driven, structure-based drug discovery engine,
Nimbus has assembled an impressive track record of delivering significant
value from the company’s scientific programs:

  *Two industry-leading research collaborations:

       *Shire plc – focused on co-development of first-in-class small
         molecule treatments for several rare genetic diseases known as
         lysosomal storage disorders (LSDs);
       *Monsanto – focused on co-development of broad-spectrum fungicides,
         with new modes of action, that will help farmers control diseases and
         promote overall plant health;

  *First to identify true drivers of potency / selectivity for important
    disease targets (ACC and IRAK4);
  *Industry-leading productivity metrics for hard targets: in silico screen
    to drug candidate in 16 months for ACC;
  *First-and-only collaboration of its type with co-founding partner
    Schrodinger, the leader in computer simulation technology;
  *First prospective use of solvation technology in multiple drug discovery
  *Unprecedented use of massively parallel cloud-computing (50k clusters).

About Fierce Biotech

FierceBiotech is an internationally-recognized, daily, free-email newsletter
and web resource providing the latest biotech news, articles, and resources
related to clinical trials, drug discovery, FDA approval and regulation,
biotech company deals and more. Reaching more than 100,000 biotech and pharma
industry professionals, FierceBiotech provides subscribers with an
authoritative analysis of the day's top stories.

About Nimbus

Nimbus Discovery, a biotechnology company, harnesses cutting-edge
computational technologies to uncover breakthroughs in small molecule
pharmacology. Nimbus focuses on medically important and highly sought-after
disease targets that have proven inaccessible to traditional industry
approaches. Nimbus’ robust pre-clinical pipeline includes novel agents for the
treatment of cancer, metabolic disease and inflammation. The company is
organized as a constellation of small, nimble teams of experienced
drug-hunters deployed across program-focused subsidiary companies. Each team
is freed from conventional barriers to scientific success, chartered to create
solutions, and geared for program asset deals with leading pharmaceutical
companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and
apply a physics-based approach that establishes a new standard for rational
drug design. Nimbus is backed by world-class life science investors, including
Atlas Venture, SR One, Lilly Ventures and Bill Gates. For more information
please visit


Nimbus Discovery, LLC
Jonathan Montagu, +1-857-999-2009
Vice President, Business Development & Operations
Suda Communications LLC
Maureen L. Suda (Media), +1-585-387-9248
Press spacebar to pause and continue. Press esc to stop.